Early intervention studies, such as the Interleukin-23 Inhibition in Very Early Psoriatic Arthritis (IVEPSA) trial, suggest that IL-23 inhibition may delay the onset of PsA in high-risk psoriasis patients by modulating subclinical inflammation, highlighting its potential as a preventive approach (Witte et al., 2025). This evidence concerns the gene IL37 and psoriasis.